Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 December 2022 | Story Leonie Bolleurs | Photo Leonie Bolleurs
Dr Refilwe Mogale
Dr Refilwe Mogale received her PhD in Chemistry. She is fascinated by the ability of chemistry and science in general to solve some of the world’s most pressing issues, such as water scarcity.

“Chemistry chose me,” says Dr Refilwe Mogale, who wanted to enrol for Psychology years ago when she decided to study at the University of the Free State (UFS). 

“On the day of registration, however, as I was standing in the queue, something inside me said this was not the right choice for me. Ultimately, I chose my second option, which was a BSc degree majoring in biology, physics, and chemistry.”

“Once I started the BSc programme, I gravitated towards chemistry, and as difficult as it was juggling classes and six-hour practical sessions, I loved it. I am fascinated by the ability of chemistry and science in general to solve some of the world’s most pressing issues, such as water scarcity, alternative generation, access to antibacterial hygiene products, as well as novel strategies to cure diseases, among many other things.”

The UFS awarded Dr Mogale a PhD in Chemistry on 9 December 2022.

Addressing a global challenge

Being passionate about applied chemistry – where scientific research can be used to create products to address everyday problems – Dr Mogale focused her thesis on Aluminium- and Zirconium-based metal organic frameworks with azobenzene and stilbene dicarboxylate ligands for use in wastewater treatment. 

She has also published multiple articles on topics of environmental chemistry and wastewater management in international journals. 

Dr Mogale is of the opinion that water pollution by financially lucrative industries and access to clean drinkable water is one of our planet’s most challenging environmental and health issues. “The waste generated by some of the industries that contribute heavily to our country’s economy, such as the textile, agricultural, and medical industries, may end up in the limited drinking water resources we have. I chose my research topic because I wanted to positively contribute to this global challenge,” she says.

“My research was based on making highly porous metal-organic frameworks (MOF) to be used in the wastewater treatment technique called adsorption,” explains Dr Mogale, describing MOFs as “really cool three-dimensional ‘sponges’ that can suck up very high amounts of gases and pollutants, trapping them in their pores. These trapped materials can later be released from the pores to be re-used when MOFs are exposed to certain stimuli.”

She continues, “Low cost and simplicity make this method attractive for industrial use. Considering our current energy crisis, other methods are not ideal, since they require large amounts of energy.” 

Focused on developing highly effective adsorbent for wastewater purification systems, Dr Mogale synthesised a novel MOF with one of the highest adsorption capacities compared to existing counterparts.

According to her, should MOFs with their incredibly high surface areas – which allow them to absorb more waste than their existing counterparts – be implemented in wastewater purification systems, they would be able to address the environmental issue of water pollution and the health issue of access to drinkable water.

Tackling everyday societal issues

She is currently doing a postdoctoral fellowship in the UFS Department of Chemistry – to broaden her knowledge in chemistry beyond MOFs. Her plans are, however, to transition to industry and ultimately entrepreneurship, where she will be able to develop scientific products that can tackle everyday societal issues. 

Dr Mogale dreams of adding value to society by practically contributing to the water crisis issue through the development of low-cost water generation and purification products.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept